GlassScriptPhysician profile
Jim A James
NPI 1588769772
$3,217.34
in general payments reported to CMS, 2019-2025
32 companies · $825 in 2025
The $825 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $89.83 · 2021: $80.23 · 2022: $466 · 2023: $751 · 2024: $565 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,991 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,990.99 |
| Education | $149.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $807.58 | 2019-2025 | Tysabri, Vumerity, Tysabri |
| Tg Therapeutics, INC. | $306.26 | 2024-2025 | |
| Argenx US, INC. | $279.98 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $265.45 | 2019-2023 | Ultomiris |
| Lilly USA, LLC | $204.27 | 2019-2025 | Kisunla |
| Teva Pharmaceuticals USA, INC. | $195.63 | 2023-2025 | Austedo Xr |
| Insightec,INC | $174.44 | 2022 | |
| Eisai INC. | $136.61 | 2023 | |
| Abbvie INC. | $108.54 | 2022-2024 | |
| Microtransponder, INC. | $75.00 | 2025 | |
| Ucb, INC. | $63.60 | 2022-2025 | Rystiggo |
| Merz Pharmaceuticals, LLC | $59.24 | 2024-2025 | Inbrija, Xeomin |
| Otsuka America Pharmaceutical, INC. | $57.33 | 2023-2025 | Rexulti |
| Genzyme Corporation | $55.62 | 2021-2023 | |
| Pfizer INC. | $55.35 | 2021-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $45.28 | 2024 | Hyqvia |
| Amneal Pharmaceuticals LLC | $38.45 | 2024-2025 | Crexont, Ongentys, Rytary |
| Genentech USA, INC. | $31.44 | 2025 | Ocrevus Zunovo |
| Astrazeneca Pharmaceuticals LP | $23.49 | 2025 | Wainua |
| Supernus Pharmaceuticals, INC. | $22.88 | 2019-2020 | |
| Sk Life Science, INC. | $21.60 | 2025 | |
| Kyowa Kirin, INC. | $20.98 | 2022 | |
| Banner Life Sciences, LLC | $20.38 | 2024 | |
| Acorda Therapeutics, INC | $19.83 | 2023 | Inbrija, Ampyra |
| Janssen Biotech, INC. | $17.50 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.40 | 2022 | |
| Abbott Laboratories | $17.31 | 2021 | |
| Livanova USA, INC. | $17.13 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Braemar Manufacturing, LLC | $15.95 | 2019 | |
| Csl Behring | $15.19 | 2025 | Hizentra |
| Allergan, INC. | $14.58 | 2020 | |
| Neurocrine Biosciences, INC. | $13.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jim James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.